Topp M, Koenigsmann M, Miresluis A, Oberberg D, Eitelbach F, Vonmarschall Z, Notter M, Reufi B, Stein H, Thiel E, Berdel W
FREE UNIV BERLIN,KLINIKUM STEGLITZ,DEPT HEMATOL ONCOL,30 HINDENBURGDAMM,W-1000 BERLIN 45,GERMANY. NATL INST BIOL STAND & CONTROLS,DIV IMMUNOL,POTTERS BAR,ENGLAND.
Int J Oncol. 1993 Aug;3(2):167-70.
In the present study we report that recombinant human (rh) interleukin 4 (IL-4) has direct, dose-dependent antiproliferative effects on the human lung cancer cell line CCL 185 in vitro as measured by a human tumor cloning assay (HTCA). The biological response of the tumor cells to rhIL-4 is correlated with expression of specific binding sites for human (h) IL-4 on the cell surface. Furthermore, we have xenotransplanted CCL 185 into BALB/c nu/nu mice. Subsequently, the mice were treated for 17 days with twice 0.5 mg/m2 rhIL-4 or control vehicle subcutaneously per day. Treatment with rhIL-4 yielded a significant inhibition of tumor growth versus control. Histology of the tumors in both groups showed no marked infiltration of the tumors with murine hematopoietic and lymphocytic cells consistent with the species specificity of IL-4. We conclude that rhIL-4 has direct antiproliferative effects on the growth of a human lung tumor cell line in vitro and in vivo which together with its regulatory effects on various effector cell populations makes this cytokine a possible candidate for experimental cancer treatment.
在本研究中，我们报告重组人（rh）白细胞介素4（IL-4）在体外对人肺癌细胞系CCL 185具有直接的、剂量依赖性的抗增殖作用，这是通过人肿瘤克隆试验（HTCA）测定的。肿瘤细胞对rhIL-4的生物学反应与细胞表面人（h）IL-4特异性结合位点的表达相关。此外，我们已将CCL 185异种移植到BALB/c nu/nu小鼠体内。随后，每天两次皮下给予小鼠0.5 mg/m2 rhIL-4或对照载体，持续治疗17天。与对照组相比，rhIL-4治疗显著抑制了肿瘤生长。两组肿瘤的组织学检查均显示，肿瘤没有被鼠造血细胞和淋巴细胞明显浸润，这与IL-4的物种特异性一致。我们得出结论，rhIL-4在体外和体内对人肺癌细胞系的生长具有直接的抗增殖作用，并且其对各种效应细胞群体的调节作用使这种细胞因子成为实验性癌症治疗的一个可能候选物。
